Abstract
Uncertainty persists regarding systemic effects of anti-vascular endothelial growth factor agents in the treatment of retinopathy of prematurity (ROP). We performed a retrospective study to investigate systemic outcomes in ROP infants treated with intravitreal bevacizumab (IVB).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
